keyword
MENU ▼
Read by QxMD icon Read
search

respimat

keyword
https://www.readbyqxmd.com/read/30261995/safety-of-tiotropium-olodaterol-in-chronic-obstructive-pulmonary-disease-pooled-analysis-of-three-large-52-week-randomized-clinical-trials
#1
Gary T Ferguson, Roland Buhl, Ulrich Bothner, Alberto de la Hoz, Florian Voß, Antonio Anzueto, Peter M A Calverley
BACKGROUND: An extensive clinical trial program supports the efficacy and safety of tiotropium/olodaterol in chronic obstructive pulmonary disease (COPD). We examined the safety of tiotropium/olodaterol compared with tiotropium in a large population of patients, focusing on cardiovascular and respiratory events. METHODS: Patients (n = 9942) who received once-daily tiotropium/olodaterol 5/5 μg or tiotropium 5 μg (via Respimat® ) in TONADO 1 & 2 and DYNAGITO were included...
October 2018: Respiratory Medicine
https://www.readbyqxmd.com/read/30193393/a-single-institution-retrospective-study-of-the-clinical-efficacy-of-tiotropium-respimat-in-never-smoking-elderly-asthmatics-with-irreversible-airflow-limitation
#2
Johsuke Hara, Kazuo Kasahara, Noriyuki Ohkura, Kenta Yamamura, Tamami Sakai, Miki Abo, Naohiko Ogawa, Keigo Saeki, Hayato Koba, Satoshi Watanabe, Yuka Uchida, Yuichi Tambo, Takashi Sone, Hideharu Kimura
OBJECTIVE: In Japan, most asthma deaths occur among the elderly. We should improve the control of asthma in elderly patients to reduce the number of deaths due to asthma. This retrospective study aimed to evaluate the efficacy of tiotropium RespimatⓇ (Tio-Res) in symptomatic, never-smoking, elderly asthmatics with irreversible airflow limitation despite the use of high-dose inhaled corticosteroids (ICS) plus long-acting β2 -adrenoceptor agonists (LABA). METHODS: The Asthma Control Test™ (ACT), pulmonary function tests, morning and evening peak flow (mPEF, ePEF, respectively, evaluated with an ASSESS® peak flow meter), and respiratory impedance (assessed with MostGraph® ) were measured before and after a minimum of one year of Tio-Res 5 µg/day administration...
September 7, 2018: Drug Research
https://www.readbyqxmd.com/read/29972656/clinical-implications-of-the-tiotropium-olodaterol-inhaler-for-patients-with-chronic-obstructive-pulmonary-disease
#3
REVIEW
Gary T Ferguson, Richard N Dalby
Oral inhalation is the recommended delivery method of medications for the treatment of patients with chronic obstructive pulmonary disease (COPD). However, patients may struggle when using the various available inhaler platforms, and, as a result, may fail to achieve the benefit of the prescribed medication. Propellant-based, pressurized metered-dose inhaler and powder-based, dry powder inhaler devices are currently the most commonly prescribed delivery systems. Each of these devices has its own advantages and challenges...
August 2018: Postgraduate Medicine
https://www.readbyqxmd.com/read/29910611/long-term-safety-of-tiotropium-olodaterol-respimat-%C3%A2-in-patients-with-moderate-to-very-severe-copd-and-renal-impairment-in-the-tonado-%C3%A2-studies
#4
Craig LaForce, Eric Derom, Ulrich Bothner, Isabel M Kloer, Matthias Trampisch, Roland Buhl
Introduction: The safety, lung function efficacy, and symptomatic benefits of combined tiotropium and olodaterol in patients with COPD were established in the 1-year TONADO® studies (NCT01431274; NCT01431287). As tiotropium is predominantly excreted by the kidneys, the long-term safety profile of tiotropium/olodaterol was investigated in patients with renal impairment in a prespecified safety analysis of the TONADO studies. Methods: These were 2 replicate, randomized, double-blind, parallel-group, 52-week Phase III studies that assessed tiotropium/olodaterol compared with tiotropium or olodaterol alone (all via Respimat® ) in patients with moderate-to-very severe COPD...
2018: International Journal of Chronic Obstructive Pulmonary Disease
https://www.readbyqxmd.com/read/29878859/in-vitro-tests-for-aerosol-deposition-vi-realistic-testing-with-different-mouth-throat-models-and-in-vitro-in-vivo-correlations-for-a-dry-powder-inhaler-metered-dose-inhaler-and-soft-mist-inhaler
#5
Xiangyin Wei, Michael Hindle, Anubhav Kaviratna, Bao K Huynh, Renishkumar R Delvadia, Dennis Sandell, Peter R Byron
BACKGROUND: In vitro-in vivo correlations (IVIVC) for lung deposition may be established by testing inhalers in vitro with realistic mouth-throat (MT) models and inhalation profiles (IP). This study was designed to compare the currently available MT models and their ability to predict in vivo lung deposition. METHODS: Budelin® Novolizer® , Ventolin® Evohaler® , and Respimat® fenoterol were chosen to represent a dry powder inhaler (DPI), metered dose inhaler (MDI), and soft mist inhaler (SMI) in tests using eight MT models: small, medium, and large Virginia Commonwealth University (VCU) models; small, medium, and large oropharyngeal consortium (OPC) models, the medium adult Alberta Idealized Throat (AIT), and the United States Pharmacopeia (USP) Induction Port, with IPs that simulated those used by volunteers in lung scintigraphy studies...
June 7, 2018: Journal of Aerosol Medicine and Pulmonary Drug Delivery
https://www.readbyqxmd.com/read/29733738/case-study-a-combination-of-mepolizumab-and-omaluzimab-injections-for-severe-asthma
#6
Rejmon Dedaj, Lindie Unsel
A Combination of Mepolizumab and Omaluzimab injections for severe asthma. INTRODUCTION: Patients with severe persistent asthma account for a large proportion of asthma morbidity and health care expenditures. In this case report we describe the use of a combination of omalizumab and mepolizumab in severe asthma with elevated IgE levels and eosinophilic phenotype. CASE STUDY: We are treating a 55 year old woman with severe persistent eosinophilic asthma and elevated IgE levels...
May 7, 2018: Journal of Asthma: Official Journal of the Association for the Care of Asthma
https://www.readbyqxmd.com/read/29722630/an-industry-update-the-latest-developments-in-therapeutic-delivery
#7
Oliver C Steinbach
The present industry update covers the period of 1 January-31 January 2018, with information sourced from company press releases, regulatory and patent agencies as well as scientific literature. Several public offerings (Gecko, Insmed), licensing (Foresee) and commercialization agreements (Alnylam, Collegium Pharmaceutical) as well as patent filings (Elute) continue to prove the sustained investments in the drug delivery market. In increasing numbers, more effective ways to deliver the active ingredient to the right location and the right dose through devices (Boehringer Ingelheim's Respimat, Medtronics' SynchroMedII) or improved compound properties through formulation (Aquestive Therapeutics' PharmFilm, Noven Pharmaceuticals' transdermal patch) are reaching the market...
May 1, 2018: Therapeutic Delivery
https://www.readbyqxmd.com/read/29719386/misuse-of-inhalers-among-copd-patients-in-a-community-hospital-in-taiwan
#8
COMPARATIVE STUDY
Chi-Yen Liang, Yi-Jen Chen, Shew-Meei Sheu, Ching-Fang Tsai, Wei Chen
Purpose: Respiratory inhalers, which directly deliver medication to the airway, are important for controlling symptoms and preventing exacerbations of chronic obstructive pulmonary disease (COPD). The inhaler misuse rate of patients with COPD in Taiwan is unclear. In this study, the inhaler techniques and patient characteristics associated with incorrect inhaler techniques among patients with COPD were evaluated. Patients and methods: This cross-sectional study enrolled 298 patients with COPD (mean age 72...
2018: International Journal of Chronic Obstructive Pulmonary Disease
https://www.readbyqxmd.com/read/29719385/treatment-of-exacerbations-as-a-predictor-of-subsequent-outcomes-in-patients-with-copd
#9
COMPARATIVE STUDY
Peter Ma Calverley, Antonio R Anzueto, Daniel Dusser, Achim Mueller, Norbert Metzdorf, Robert A Wise
Rationale: Exacerbations of COPD are managed differently, but whether treatment of one exacerbation predicts the likelihood of subsequent events is unknown. Objective: We examined whether the treatment given for exacerbations predicted subsequent outcomes. Methods: This was a post-hoc analysis of 17,135 patients with COPD from TIOtropium Safety and Performance In Respimat® (TIOSPIR® ). Patients treated with tiotropium with one or more moderate to severe exacerbations on study were analyzed using descriptive statistics, logistic and Cox regression analysis, and Kaplan-Meier plots...
2018: International Journal of Chronic Obstructive Pulmonary Disease
https://www.readbyqxmd.com/read/29605203/in-vitro-and-clinical-characterization-of-the-valved-holding-chamber-aerochamber-plus-%C3%A2-flow-vu-%C3%A2-for-administrating-tiotropium-respimat-%C3%A2-in-1-5-year-old-children-with-persistent-asthmatic-symptoms
#10
Herbert Wachtel, Mark Nagel, Michael Engel, Georges El Azzi, Ashish Sharma, Jason Suggett
BACKGROUND: When characterizing inhalation products, a comprehensive assessment including in vitro, pharmacokinetic (PK), and clinical data is required. We conducted a characterization of tiotropium Respimat® when administered with AeroChamber Plus® Flow-Vu® anti-static valved holding chamber (test VHC) with face mask in 1-5-year-olds with persistent asthmatic symptoms. METHODS: In vitro tiotropium dose and particle size distribution delivered into a cascade impactor were evaluated under fixed paediatric and adult flow rates between actuation and samplings...
April 2018: Respiratory Medicine
https://www.readbyqxmd.com/read/29520137/factors-associated-with-appropriate-inhaler-use-in-patients-with-copd-lessons-from-the-real-survey
#11
MULTICENTER STUDY
David Price, Dorothy L Keininger, Boomi Viswanad, Matthias Gasser, Susann Walda, Florian S Gutzwiller
Background: Nonadherence to medication and incorrect use of inhalers represent significant barriers to optimal disease management of patients with chronic obstructive pulmonary disease (COPD). Thus, health care professionals (HCPs) play a critical role in educating their patients on appropriate inhaler use and in ensuring medication adherence. However, many patients do not receive appropriate inhaler training or have not had their inhaler technique checked. Methods: The Real-life Experience and Accuracy of inhaLer use (REAL) survey was a computer-assisted, telephonic survey consisting of 23 questions gathering real-world information on correct inhaler use, inhalation technique, device attributes, adherence, dosing accuracy, training, correct device use, ease of use, and factors that influence patient adherence in commercially available inhalers delivering COPD maintenance therapy...
2018: International Journal of Chronic Obstructive Pulmonary Disease
https://www.readbyqxmd.com/read/29497289/seasonal-variations-in-exacerbations-and-deaths-in-patients-with-copd-during-the-tiospir-%C3%A2-trial
#12
RANDOMIZED CONTROLLED TRIAL
Robert A Wise, Peter Ma Calverley, Kerstine Carter, Emmanuelle Clerisme-Beaty, Norbert Metzdorf, Antonio Anzueto
Background: Although COPD exacerbations are known to occur more frequently in winter, there is little information on hospitalizations and cause-specific mortality. This study aimed to examine seasonal variations in mortality and exacerbations in patients with COPD during the TIOtropium Safety and Performance In Respimat® (TIOSPIR® ) trial. Patients and methods: TIOSPIR was a large-scale, multicenter trial, which assessed the safety and efficacy of tiotropium delivered via HandiHaler® (18 μg once daily) or Respimat® Soft Mist™ (2...
2018: International Journal of Chronic Obstructive Pulmonary Disease
https://www.readbyqxmd.com/read/29462195/assessment-of-inhalation-flow-patterns-of-soft-mist-inhaler-co-prescribed-with-dry-powder-inhaler-using-inspiratory-flow-meter-for-multi-inhalation-devices
#13
Daiki Hira, Hiroyoshi Koide, Shigemi Nakamura, Toyoko Okada, Kazunori Ishizeki, Masafumi Yamaguchi, Setsuko Koshiyama, Tetsuya Oguma, Kayoko Ito, Saori Funayama, Yuko Komase, Shin-Ya Morita, Kohshi Nishiguchi, Yasutaka Nakano, Tomohiro Terada
The patients' inhalation flow pattern is one of the significant determinants for clinical performance of inhalation therapy. However, the development of inhalation flow meters for various inhalation devices has been unable to keep up with the increasing number of newly launched inhalation devices. In the present study, we developed simple attachment orifices for the inhalation flow pattern monitoring system, which are suitable for all commercial inhalers, and investigated the efficacy of the system on the clinical inhalation instruction for patients co-prescribed dry powder inhaler (DPI) and soft mist inhaler (SMI)...
2018: PloS One
https://www.readbyqxmd.com/read/29420077/tiotropium-added-to-low-to-medium-dose-inhaled-corticosteroids-ics-versus-low-to-medium-dose-ics-alone-for-adults-with-mild-to-moderate-uncontrolled-persistent-asthma-a-systematic-review-and-meta-analysis
#14
Liqun Wang, Ruirui Zhou, Xiaohui Xie
OBJECTIVE: To assess the efficacy and safety profile of tiotropium when added to low- to medium-dose inhaled corticosteroid (ICS) regimen versus low- to medium-dose ICS alone for adults with mild to moderate uncontrolled persistent asthma. DATA SOURCES: The online databases Pubmed, Embase and the Cochrane Library were searched for relevant data published up to November 14, 2017; we also conducted a supplementary search using clinicaltrials.gov. STUDY SELECTIONS: Only randomized control trials were included in this review...
February 8, 2018: Journal of Asthma: Official Journal of the Association for the Care of Asthma
https://www.readbyqxmd.com/read/29368127/efficacy-and-safety-of-tiotropium-in-children-and-adolescents
#15
REVIEW
Eckard Hamelmann, Stanley J Szefler
Asthma is one of the most common chronic diseases in children, with a high proportion of patients demonstrating poor control despite the availability of disease management guidelines. Global Initiative for Asthma guidelines include tiotropium as an add-on therapy option at Steps 4 and 5 in patients aged ≥ 12 years with a history of exacerbations, and tiotropium delivered via the Respimat® Soft Mist™ Inhaler has recently been approved for use as once-daily maintenance therapy for children with asthma over the age of 6 years in the USA...
March 2018: Drugs
https://www.readbyqxmd.com/read/29361462/safety-and-efficacy-of-tiotropium-in-children-aged-1-5-years-with-persistent-asthmatic-symptoms-a-randomised-double-blind-placebo-controlled-trial
#16
RANDOMIZED CONTROLLED TRIAL
Elianne J L E Vrijlandt, Georges El Azzi, Mark Vandewalker, Ned Rupp, Thomas Harper, LeRoy Graham, Stanley J Szefler, Petra Moroni-Zentgraf, Ashish Sharma, Sebastian D Vulcu, Ralf Sigmund, Bo Chawes, Michael Engel, Hans Bisgaard
BACKGROUND: Few studies have assessed the safety and efficacy of potential asthma medications in children younger than 5 years. We descriptively assessed the safety and efficacy of tiotropium, a long-acting anticholinergic drug, in children aged 1-5 years with persistent asthmatic symptoms. METHODS: This exploratory 12-week, randomised, double-blind, placebo-controlled, parallel-group, phase 2/3, regulatory multicentre trial was done at 32 hospitals, clinics, and clinical research units in 11 countries in Asia, Europe, and North America...
February 2018: Lancet Respiratory Medicine
https://www.readbyqxmd.com/read/29317111/demographic-characteristics-and-clinical-outcomes-in-patients-from-latin-america-versus-the-rest-of-the-world-a-tiospir-%C3%A2-post-hoc-analysis
#17
RANDOMIZED CONTROLLED TRIAL
Antonio Anzueto, Peter M A Calverley, Achim Mueller, Norbert Metzdorf, Michaela Haensel, José R Jardim, Emilio Pizzichini, Horacio Giraldo, Alejandra Ramirez-Venegas, Eduardo R Giugno
INTRODUCTION: Geographical variations may impact outcomes in chronic obstructive pulmonary disease (COPD). We evaluated differences in baseline characteristics and outcomes between patients enrolled in Latin America compared with the rest of the world (RoW) in the TIOtropium Safety and Performance In Respimat® (TIOSPIR® ) trial. METHODS: TIOSPIR® , a 2-3-year, randomized, double-blind trial (n=17116; treated set), compared safety and efficacy of once-daily tiotropium Respimat® 5 and 2...
March 2018: Archivos de Bronconeumología
https://www.readbyqxmd.com/read/29279056/a-review-of-the-efficacy-and-safety-of-once-daily-tiotropium-respimat-2-5-micrograms-in-adults-and-adolescents-with-asthma
#18
Eli O Meltzer, William E Berger
BACKGROUND: Despite current guidelines, many patients with asthma remain symptomatic, particularly those intolerant of, unresponsive to, or uncontrolled by long-acting beta 2-agonists (LABAs). Tiotropium bromide, delivered through the Respimat soft-mist inhaler in 2 puffs of 1.25 micrograms each, is approved for the long-term, maintenance treatment of asthma in patients aged ≥6 years. OBJECTIVE: An overview of the use of once-daily tiotropium Respimat 2.5 micrograms in adults and adolescents with varying degrees of asthma severity...
January 6, 2018: Allergy and Asthma Proceedings:
https://www.readbyqxmd.com/read/29206566/preferences-and-inhalation-techniques-for-inhaler-devices-used-by-patients-with-chronic-obstructive-pulmonary-disease
#19
Roxanne Bournival, Raphaël Coutu, Nicolas Goettel, Chun Dian Yang, Antoine Cantin-Lafleur, Catherine Lemieux, Anne-Marie Lévesque, Jean-François Patenaude-Monette, François-Olivier Roy, Lucie Blais, Fanny Arbour, Anne Fillion, Marie-France Beauchesne
BACKGROUND: Inhaler technique and patient preferences are often overlooked when selecting maintenance treatments for patients with chronic obstructive pulmonary disease (COPD), but are important issues in ensuring drug efficacy and patient adherence. Few data on these issues are available for new inhalation devices. OBJECTIVES: To evaluate the inhalation techniques for the HandiHaler® , Breezhaler® , Genuair® , and Respimat® inhalation devices, and patient preferences for the three latter inhalers that were recently developed...
August 2018: Journal of Aerosol Medicine and Pulmonary Drug Delivery
https://www.readbyqxmd.com/read/29174062/tiotropium-respimat-add-on-is-efficacious-in-symptomatic-asthma-independent-of-t2-phenotype
#20
Thomas B Casale, Eric D Bateman, Mark Vandewalker, J Christian Virchow, Hendrik Schmidt, Michael Engel, Petra Moroni-Zentgraf, Huib A M Kerstjens
BACKGROUND: Adding tiotropium to existing inhaled corticosteroid (ICS) maintenance therapy with or without a long-acting β2 -agonist (LABA) has been shown to be beneficial in patients with symptomatic asthma. OBJECTIVE: To assess whether responses to tiotropium Respimat add-on therapy were influenced by patients' T2 status. METHODS: In this exploratory study, data from 4 phase III trials were analyzed: once-daily tiotropium 5 μg or placebo as add-on to ICS + LABA (PrimoTinA-asthma; 2 replicate trials; NCT00772538/NCT00776984; n = 912); once-daily tiotropium 5 μg or 2...
May 2018: Journal of Allergy and Clinical Immunology in Practice
keyword
keyword
168015
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"